Choose from over 1,000 restaurants
The pioneering drug, an anti-clotting agent for people with a rare inherited disease, is made from the milk of goats whose DNA has been modified to incorporate human genes.
The drug, ATryn, sets a precedent for using modified animal proteins, and despite protests from animal welfare campaigners that “Frankendrugs” are ethically unjustifiable, the technology is sure to take off.
Drug companies have long suspected that there is profit in turning farm animals into pharmaceutical “factories”, a process known as pharming.
In theory, pharmed animals could also be used to produce insulin for diabetics, blood-clotting factor to treat haemophiliacs and a range of other proteins.
Pharming could become integral to the drugs industry if the costs fall substantially below those for current production systems. Chickens, cows, rabbits are already undergoing trials.
However, proposals to modify pigs with human genes so their organs could be transplanted into people have largely been abandoned for fear of transmitting viruses.
ATryn was developed to treat patients with hereditary antithrombin deficiency (HAD), which makes people vulnerable to deep-vein thrombosis. Tom Newberry, a spokesman for GTC Biotherapeutics, the American company that developed the drug, said it would be available in Britain and Europe from mid-2007. “This process has the potential to revolutionise the pharmaceutical industry,” he said.
Conventional methods of creating blood proteins — such as insulin, growth hormone and antithrombin from donated blood and body tissues — are vulnerable to the risk of infection.
In one case, thousands of haemophiliacs contracted HIV when they were given clotting factors from infected donors. In the 1980s such scandals prompted the creation of a new system of “bioreactors” in which cells, usually taken from the ovaries of Chinese hamsters, were genetically modified to produce a human protein and then cultured.
This system has worked well for about two decades, but it is hard for such cells to make protein molecules, especially larger ones, with exactly the right properties. It is also expensive to produce large amounts.
GTC created the first transgenic goats 15 years ago by taking fertilised goat egg cells and injecting them with the human gene for the antithrombin protein. The gene incorporated itself into the DNA of the embryonic goats, which were then implanted in surrogate mothers.
Another biotech company, the Dutch firm Pharming, is close to bringing drugs to market. Last month it lodged an application with the European Medicines Agency, the body that approved ATryn, for a second drug derived from transgenic animals.
Its drug, Rhucin, is intended to treat hereditary angioedema, a disease characterised by the painful, and sometimes fatal, swelling of soft tissues.
Transgenic animals are a mainstay of medical research: mice and rats are already used to test the function of various genes.
Professor Steve Brown, director of the Medical Research Council’s mammalian genetics unit at Harwell, Oxfordshire, said such research was shedding light on diseases ranging from cancer to deafness in children.
“We have, for example, identified the mouse genes that cause a condition analogous to glue ear in humans,” he said. “In 10 years we will have real insight into many more conditions.”
Others are uneasy at turning animals into research tools and drug factories. Genewatch, a campaign group that tracks developments in genetic engineering, said in a report: “This represents a further step towards seeing animals purely as commodities without regard for their inherent worth as sentient beings.”
However, even the protesters might approve of research at Minos BioSystems, a British biotech company. It plans to produce drugs from insect larvae. In a business plan reminiscent of the sci-fi horror film The Fly, the company proposes creating house flies with human genes to produce human blood protein.
Industry sectors news at a glance. Interactive heatmap, video and podcast
Get ready for the winter sports season, with our resort guides and snow reports
We are backing British business, what is the confidence of the nation and what businesses are succeeding?
Growing demand for energy, oil that is harder to reach and the rise of carbon dioxide emissions. We examine the energy challenge
In this special section we explore new food trends to help improve your dinner party and impress guests
Enjoy further reading from Travel to Fashion, Business to Sport, discover more
Shortcuts to help you find sections and articles
1998
£47,955
2004
£56,950
Essex
Check your free Experian credit report before applying
Car Insurance
From £44,589
HM PRISON SERVICE
Nationwide
Competitive
Hickman and Rose
London
Romulus Construction Limited
London
£100,000
Home Office
Liverpool
Moments from Battersea Park.
For sale with Winkworth
Find out about shared ownership.
See your free Experian credit report beforehand
Pay for an Ocean view and receive a free upgrade to a Balcony stateroom + up to $200 Free Onboard Spend!
Get covered on your travels with a superb range of policies at great prices. Visit InsureandGo.com
Wintersun - inspiration for your winter holiday
Contact our advertising team for advertising and sponsorship in Times Online, The Times and The Sunday Times, or place your advertisement.
Times Online Services: Dating | Jobs | Property Search | Used Cars | Holidays | Births, Marriages, Deaths | Subscriptions | E-paper
News International associated websites: Globrix Property Search | Milkround
Copyright 2010 Times Newspapers Ltd.
This service is provided on Times Newspapers' standard Terms and Conditions. Please read our Privacy Policy.To inquire about a licence to reproduce material from Times Online, The Times or The Sunday Times, click here.This website is published by a member of the News International Group. News International Limited, 1 Virginia St, London E98 1XY, is the holding company for the News International group and is registered in England No 81701. VAT number GB 243 8054 69.